- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,736
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
- Interventions
- Bortezomib, NK cells
- Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
- Interventions
- TST005
- Drug
- Lead sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Dallas, Texas • San Antonio, Texas
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
- Interventions
- RLY-2608, Fulvestrant, Palbociclib 125mg, Ribociclib 400mg, Ribociclib 600mg, PF-07220060 100mg, PF-07220060 300 mg
- Drug
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more
- Conditions
- Endometrial Cancer, Malignant Solid Tumour
- Interventions
- Puxitatug Samrotecan, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 68
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 59 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
- Interventions
- AFNT-211
- Drug
- Lead sponsor
- Affini-T Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
- Conditions
- Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
- Interventions
- Sapanisertib, Ziv-Aflibercept
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Interventions
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Drug
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- NMS-03305293
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Interventions
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Solid Tumor
- Interventions
- Neratinib, Paclitaxel, Pertuzumab, Trastuzumab
- Drug
- Lead sponsor
- Michelle Melisko
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- CGT9486, Pexidartinib, Sunitinib
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 6
- States / cities
- Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Gemcitabine, Docetaxel, Temozolomide, Cisplatin, Erlotinib, LY573636
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Denver, Colorado + 16 more
- Conditions
- Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Interventions
- Dexamethasone, Exercise Intervention, Placebo Administration
- Drug · Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
- Interventions
- CF33-hNIS, Pembrolizumab, Modified FOLFOX
- Biological · Drug
- Lead sponsor
- Imugene Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Interventions
- ASP5834, panitumumab
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- GTI-2040, oxaliplatin, capecitabine, pharmacological study, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Malignant Solid Neoplasm
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Positron Emission Tomography, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cancer
- Interventions
- BMS-906024
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
- Interventions
- tolododekin alfa, Cemiplimab
- Drug
- Lead sponsor
- Ankyra Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Tumors, Non Hodgkin's Lymphoma
- Interventions
- MGCD0103
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pyroxamide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma, Recurrent Colorectal Carcinoma, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Hypopharyngeal Carcinoma AJCC v7, Stage I Major Salivary Gland Cancer AJCC v7, Stage I Nasopharyngeal Carcinoma AJCC v7, Stage I Oral Cavity Cancer AJCC v6 and v7, Stage I Oropharyngeal Carcinoma AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC v6 and v7, Stage II Major Salivary Gland Cancer AJCC v7, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage II Oral Cavity Cancer AJCC v6 and v7, Stage II Oropharyngeal Carcinoma AJCC v6 and v7, Stage IIA Colorectal Cancer AJCC v7, Stage IIB Colorectal Cancer AJCC v7, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC v7, Stage III Laryngeal Cancer AJCC v6 and v7, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Oral Cavity Cancer AJCC v6 and v7, Stage III Oropharyngeal Carcinoma AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC v7, Stage IVA Laryngeal Cancer AJCC v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC v7, Stage IVB Laryngeal Cancer AJCC v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Carcinoma AJCC v7, Metastatic or Locally Unresectable Solid Tumor
- Interventions
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
- Interventions
- OR502, Cemiplimab
- Drug
- Lead sponsor
- OncoResponse, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more